Phase 3 hidradenitis trials reveal limits of single-pathway inhibition

Topline data from two phase 3 trials (KEEPsAKE 1 and 2) examining risankizumab for moderate-to-severe hidradenitis suppurativa showed the therapy met its primary endpoint of HiSCR50, achieving clinical response in roughly 47% of participants at week 16. However, placebos performed higher than projected, and absolute clearance rates trailed analyst expectations. Hidradenitis suppurativa affects roughly 1% of the population, causing chronic, painful subcutaneous nodules that resist simple therapeutic intervention.

Risankizumab selectively targets the p19 subunit of interleukin-23. The modest delta over control groups reinforces that systemic inflammation rarely follows a linear trajectory through one cytokine. When systemic symptoms span immune, endocrine, and cutaneous domains, clinical drug development often relies on crude clinical lesion counts that fail to capture phenotypic diversity across patient cohorts.

If you manage a recurring inflammatory or dermatological condition, document your flare triggers alongside objective lab markers such as high-sensitivity C-reactive protein and absolute neutrophil counts. Bring structured longitudinal logs to your specialist rather than relying on point-in-time visual inspections.